Table 16.

The assessment of patients’ survival depending on sex, age, stage of disease, diagnostic procedures and treatment

Variable	Survival rate (months)			P-value
<12 N=104	12–24 N=46	>24 N=83
Gender:				0.034
Female	17 (16.3%)	12 (26.1%)	27 (32.5%)
Male	87 (83.7%)	34 (73.9%)	56 (67.5%)
Age (years):				0.036
<50	11 (10.6%)	5 (10.9%)	15 (18.1%)
50–60	40 (38.5%)	16 (34.8%)	26 (31.3%)
60–70	34 (32.7%)	24 (52.2%)	34 (41.0%)
>70	19 (18.3%)	1 (2.1%)	8 (9.6%)
Degree of spread to regional				<0.001
N1	10 (9.6%)	9 (19.6%)	14 (16.9%)
N2	23 (22.1%)	25 (54.4%)	52 (62.6%)
N3	71 (68.3%)	12 (26.1%)	17 (20.5%)
Panendoscopy revealed primary tumor	n=23	n=31	n=51	0.802
Yes	7 (30.4%)	12 (38.7%)	17 (33.3%)
No	16 (69.6%)	19 (61.3%)	34 (66.7%)
PET - revealed primary tumor	n=21	n=16	n=33	0.757
Yes	8 (38.1%)	8 (50.0%)	15 (45.5%)
No	13 (61.9%)	8 (50.0%)	18 (54.5%)
Cervical lymph node groups:
I	7 (6.7%)	1 (2.2%)	1 (1.2%)	0.120
II	91 (87.5%)	39 (84.8%)	75 (90.4%)	0.634
III	70 (67.3%)	28 (60.9%)	46 (55.4%)	0.249
IV	41 (39.4%)	7 (15.2%)	11 (13.3%)	<0.001
V	23 (22.1%)	3 (6.5%)	5 (6.0%)	0.002
VI	2 (1.9%)	0 (0.0%)	0 (0.0%)	0.286
Tonsillectomy	4 (3.8%)	14 (30.4%)	19 (22.9%)	<0.001
Pathologic type:				0.090
1 - squamous cell carcinoma	90 (86.5%)	38 (82.6%)	74 (89.2%)
2 – adenocarcinoma	2 (1.9%)	3 (6.5%)	3 (3.6%)
3 – melanoma	1 (1.0%)	4 (8.7%)	3 (3.6%)
4 – lymphoma	0 (0.0%)	1 (2.2%)	0 (0.0)
5 – other	11 (10.6%)	0 (0.0%)	3 (3.6%)
Surgery	34 (32.7%)	24 (52.2%)	51 (61.4%)	<0.001
Radiotherapy	53 (51.0%)	40 (87.0%)	73 (88.0%)	<0.001
Chemotherapy	50 (48.1%)	30 (65.2%)	55 (66.3%)	0.023
ECOG performance status:				<0.001
0	19 (18.3%)	25 (54.3%)	59 (71.1%)
1	55 (52.9%)	20 (43.5%)	21 (25.3%)
2	23 (22.1%)	1 (2.2%)	2 (2.4%)
3	6 (5.8%)	0 (0.0%)	1 (1.2%)
4	1 (1.0%)	0 (0.0%)	0 (0.0%)
Treatment:				<0.001
Radical	23 (22.1%)	35 (76.1%)	77 (92.8%)
Palliative	81 (77.9%)	11 (23.9%)	6 (7.2%)

Note: Bold values represent statistically significant.

Abbreviations: ECOG, Eastern Cooperative Oncology Group.